Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum

By afschroeder • September 4, 2026

Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang L, von Kleist M, Hendrix CW, Momper JD, Bies R, Scott RK. Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum. J Clin Pharmacol. 2026 Sep;66(9):e70278. doi: 10.1002/jcph.70278. PMID: 42687587; PMCID: PMC13539293.

Tags: antiretroviral, HIV, Infectious Diseases, population pharmacokinetics, pregnancy, Publications, quantitative pharmacology, trial simulation

Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system ImPrEP CAB Brasil: a hybrid type-2 implementation-effectiveness cohort study

Grinsztejn B, Torres TS, Hoagland B, Coutinho C, Silva MST, Leite IC, Cunha M, Derrico M, Jalil EM, Cardoso SW, Trefiglio R, Farias A, Mourão[...]

Diagnostics for Hemorrhagic Fever Viruses: Lassa Fever as an Example

Dhar B, Espinoza N, Farzani T, Baudi I, Nosamiefan D, Garcia CY, Allan-Blitz LT, Samani P, Happi C, Sabeti P. Diagnostics for Hemorrhagic Fever Viruses:[...]

Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis

Gu Y, Gebremariam T, Ibrahim BA, Harb K, Chan A, Ibrahim AS. Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis. J Fungi (Basel).[...]